

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

NCT06467344

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Ascidian Therapeutics, Inc
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (4)

- Presence of mutations in the ABCA4 gene
- ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)
- Area of atrophy located in the macula of the study eye
- BCVA of 20/50 (0.4 logMAR) or worse

Exclusion (3)

- The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
- Retinal disease other than ABCA4-related retinopathy
- Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.

Locations (10 total)

University of San Francisco, San Francisco, California, United States
Vitreous Retinal Associates, Gainesville, Florida, United States
Bascom Palmer Eye Institute, Miami, Florida, United States
... and 7 more locations